Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Risk factors for and management of cognitive dysfunction in multiple sclerosis

Abstract

Cognitive impairment is common in multiple sclerosis (MS), especially when assessed by neuropsychological tests that emphasize mental processing speed, episodic memory, and some aspects of executive function. In this Review, we question why some MS patients develop severe impairment in cognitive abilities, while cognitive ability remains intact in others. We find that the heterogeneity in neuropsychological presentation among patients with MS reflects the influence of many factors, including genetics, sex, intelligence, disease course, comorbid neuropsychiatric illness, and health behaviors. Neuropsychological deficits are also robustly correlated with brain MRI metrics. Male patients with early evidence of cerebral gray matter atrophy are most prone to impairment, whereas high premorbid intelligence improves the neuropsychological prognosis. Routine evaluation of cognition is useful for helping patients to navigate problems related to activities of daily living and work disability and, if reliable methods are employed, cognitive decline can be detected and included among the many clinical signs of disease progression or treatment failure. Pharmacological treatments for neuropsychological impairment are on the horizon, although presently no firm medical indications exist for the condition.

Key Points

  • Multiple sclerosis (MS) is both an inflammatory and neurodegenerative disease, with cognition affected in roughly 50% of patients

  • Cognitive impairment is most commonly detected on tests of mental processing speed and episodic memory

  • Neuropsychological testing is sensitive to MS cognitive disorder and can be applied in brief, routine evaluations

  • Male patients with low education or intelligence, early onset of MS, and evidence of cerebral gray matter atrophy seem most prone to impairment, whereas high premorbid intelligence is protective

  • To date, evidence for any particular medical therapy improving cognition in MS has been inconsistent, despite being an area of intense investigation

  • Future MS clinical trials should include cognitive outcome measures and use neuropsychological tests that are reliable and are known to reveal clinically meaningful changes

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Global and regional tissue-specific brain atrophy in MS.

References

  1. 1

    Hauser, S. L., Oksenberg, J. R., Hauser, S. L. & Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52, 61–76 (2006).

    CAS  PubMed  Google Scholar 

  2. 2

    Charcot, J. M. Lectures on the Diseases of the Nervous System (New Sydenham Society, London, 1877).

    Google Scholar 

  3. 3

    Rao, S. M., Leo, G. J., Bernardin, L. & Unverzagt, F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41, 685–691 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4

    [No authors listed] Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655–661 (1993).

  5. 5

    Jacobs, L. D. et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exascerbating–remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult. Scler. 1, 118–135 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6

    Johnson, K. P. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50, 701–708 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7

    Amato, M. P., Zipoli, V. & Portaccio, E. Multiple-sclerosis related cognitive changes: a review of cross-sectional and longitudinal studies. J. Neurol. Sci. 245, 41–46 (2006).

    PubMed  PubMed Central  Google Scholar 

  8. 8

    Benedict, R. H. B. et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin. Neuropsychol. 16, 381–397 (2002).

    PubMed  PubMed Central  Google Scholar 

  9. 9

    Chiaravalloti, N. D. & DeLuca, J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7, 1139–1151 (2008).

    PubMed  PubMed Central  Google Scholar 

  10. 10

    Patti, F. Cognitive impairment in multiple sclerosis. Mult. Scler. 15, 2–8 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11

    Patti, F. et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult. Scler. 15, 779–788 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Benedict, R. H. B. et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 12, 549–558 (2006).

    PubMed  PubMed Central  Google Scholar 

  13. 13

    Carone, D., Benedict, R. H. B., Munschauer, F. E. III, Fishman, I. & Weinstock-Guttman, B. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J. Int. Neuropsychol. Soc. 11, 574–583 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14

    Wechsler, D. Wechsler Adult Intelligence Scale, 4th edn (Pearson, New York, 2008).

    Google Scholar 

  15. 15

    Lezak, M. Neuropsychological Assessment (Oxford University Press, New York, 1995).

    Google Scholar 

  16. 16

    DeLuca, J., Chelune, G. J., Tulsky, D. S., Lengenfelder, J. & Chiaravalloti, N. D. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J. Clin. Exp. Neuropsychol. 26, 550–562 (2004).

    PubMed  PubMed Central  Google Scholar 

  17. 17

    Archibald, C. J. & Fisk, J. D. Information processing efficiency in patients with multiple sclerosis. J. Clin. Exp. Neuropsychol. 22, 686–701 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18

    Rao, S. M. On the nature of memory disturbance in multiple sclerosis. J. Clin. Exp. Neuropsychol. 11, 699–712 (1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    DeLuca, J., Gaudino, E. A., Diamond, B. J., Christodoulou, C. & Engel, R. A. Acquisition and storage deficits in multiple sclerosis. J. Clin. Exp. Neuropsychol. 20, 376–390 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20

    Kalmar, J. H., Gaudino, E. A., Moore, N. B., Halper, J. & Deluca, J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology 22, 442–449 (2008).

    PubMed  PubMed Central  Google Scholar 

  21. 21

    Langdon, D. W. & Thompson, A. J. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult. Scler. 5, 94–100 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22

    Rao, S. M. et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41, 692–696 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Benedict, R. H. B. et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J. Neurol. Sci. 231, 29–34 (2005).

    PubMed  PubMed Central  Google Scholar 

  24. 24

    Buschke, F. & Fuld, P. A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24, 1019–1025 (1974).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25

    Barbizet, J. & Cany, E. Clinical and psychometric study of a patient with memory disturbances. Int. J. Neurol. 7, 44–54 (1968).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26

    Benton, A. L. & Hamsher, K. Multilingual Aphasia Examination (AJA Associates, Iowa City, 1989).

    Google Scholar 

  27. 27

    Borkowski, J. G., Benton, A. L. & Spreen, O. Word fluency and brain damage. Neuropsychologia 5, 135–140 (1967).

    Google Scholar 

  28. 28

    Gronwall, D. M. A. Paced auditory serial addition task: a measure of recovery from concussion. Percept. Mot. Skills 44, 367–373 (1977).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29

    Rao, S. M. Neuropsychological Screening Battery for Multiple Sclerosis (National Multiple Sclerosis Society, New York, 1991).

    Google Scholar 

  30. 30

    Smith, A. Symbol Digit Modalities Test: Manual (Western Psychological Services, Los Angeles, 1982).

    Google Scholar 

  31. 31

    Huijbregts, S. C., Kalkers, N. F., de Sonneville, L. M., de Groot, V. & Polman, C. H. Cognitive impairment and decline in different MS subtypes. J. Neurol. Sci. 245, 187–194 (2006).

    PubMed  PubMed Central  Google Scholar 

  32. 32

    Christodoulou, C. et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 60, 1793–1798 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33

    Amato, M. P. et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63, 89–93 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34

    Camp, S. J. et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 128, 2891–2898 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35

    Sepulcre, J. et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult. Scler. 12, 187–195 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36

    Portaccio, E. et al. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. Mult. Scler. 16, 611–617 (2010).

    PubMed  PubMed Central  Google Scholar 

  37. 37

    Peyser, J. M., Rao, S. M., LaRocca, N. G. & Kaplan, E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neurol. 47, 94–97 (1990).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38

    Benedict, R. H. B., Schretlen, D., Groninger, L., Dobraski, M. & Shpritz, B. Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol. Assess. 8, 145–153 (1996).

    Google Scholar 

  39. 39

    Benedict, R. H. B. Brief Visuospatial Memory Test—Revised: Professional Manual (Psychological Assessment Resources, Odessa, FL, 1997).

    Google Scholar 

  40. 40

    Delis, D. C., Kramer, J. H., Kaplan, E. & Ober, B. A. California Verbal Learning Test Manual: Second Edition, Adult Version (Psychological Corporation, San Antonio, TX, 2000).

    Google Scholar 

  41. 41

    Delis, D. C., Kaplan, E. & Kramer, J. H. Delis–Kaplan Executive Function System (Psychological Corporation, San Antonio, TX, 2001).

    Google Scholar 

  42. 42

    Benton, A. L., Sivan, A. B., Hamsher, K., Varney, N. R. & Spreen, O. Contributions to Neuropsychological Assessment (Oxford University Press, New York, 1994).

    Google Scholar 

  43. 43

    Strober, L. et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult. Scler. 15, 1077–1084 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Duquin, J. A., Parmenter, B. A. & Benedict, R. H. B. Influence of recruitment and participation bias on neuropsychological research among MS patients. J. Int. Neuropsychol. Soc. 14, 494–498 (2008).

    PubMed  PubMed Central  Google Scholar 

  45. 45

    Parmenter, B. A. et al. Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J. Clin. Exp. Neuropsychol. 29, 215–223 (2007).

    PubMed  PubMed Central  Google Scholar 

  46. 46

    Benedict, R. H. B. Effects of using same vs alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J. Int. Neuropsychol. Soc. 11, 727–736 (2005).

    PubMed  PubMed Central  Google Scholar 

  47. 47

    Simon, J. H. et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53, 139–148 (1999).

    CAS  Google Scholar 

  48. 48

    Camp, S. J. et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 122, 1341–1348 (1999).

    PubMed  PubMed Central  Google Scholar 

  49. 49

    Deloire, M. S. et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 519–526 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50

    Huijbregts, S. C. et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 63, 335–339 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51

    Nocentini, U., Giordano, A., Di Vincenzo, S., Panella, M. & Pasqualetti, P. The Symbol Digit Modalities Test—oral version: Italian normative data. Funct. Neurol. 21, 93–96 (2006).

    PubMed  PubMed Central  Google Scholar 

  52. 52

    Nocentini, U. et al. Cognitive dysfunction in patients with relapsing–remitting multiple sclerosis. Mult. Scler. 12, 77–87 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53

    Parmenter, B. A., Testa, S. M., Schretlen, D. J., Weinstock-Guttman, B. & Benedict, R. H. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 16, 6–16 (2010).

    PubMed  PubMed Central  Google Scholar 

  54. 54

    Parmenter, B. A., Weinstock-Guttman, B., Garg, N., Munschauer, F. & Benedict, R. H. B. Screening for cognitive impairment in MS using the Symbol Digit Modalities Test. Mult. Scler. 13, 52–57 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55

    Benedict, R. H. B. et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch. Neurol. 63, 1301–1306 (2006).

    PubMed  PubMed Central  Google Scholar 

  56. 56

    Bermel, R. A., Sharma, J., Tjoa, C. W., Puli, S. R. & Bakshi, R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J. Neurol. Sci. 208, 57–65 (2003).

    PubMed  PubMed Central  Google Scholar 

  57. 57

    Benedict, R. H., Ramasamy, D., Munschauer, F., Weinstock-Guttman, B. & Zivadinov, R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J. Neurol. Neurosurg. Psychiatry 80, 201–206 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Tekok-Kilic, A. et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 36, 1294–1300 (2007).

    PubMed  PubMed Central  Google Scholar 

  59. 59

    Benedict, R. H. B. et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult. Scler. 13, 722–730 (2007).

    PubMed  PubMed Central  Google Scholar 

  60. 60

    Benedict, R. H. B. et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am. J. Neuroradiol. 26, 1824–1831 (2005).

    PubMed  PubMed Central  Google Scholar 

  61. 61

    Benedict, R. H. B., Carone, D. & Bakshi, R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J. Neuroimaging 14 (Suppl. 3), 36S–45S (2004).

    PubMed  PubMed Central  Google Scholar 

  62. 62

    Benedict, R. H. B. et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch. Neurol. 61, 226–230 (2004).

    PubMed  PubMed Central  Google Scholar 

  63. 63

    Drake, A. S. et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult. Scler. 16, 228–237 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64

    Fischer, J. S., Rudick, R. A., Cutter, G. R. & Reingold, S. C. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5, 244–250 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65

    Rosti, E., Hamalainen, P., Koivisto, K. & Hokkanen, L. PASAT in detecting cognitive impairment in relapsing–remitting MS. Appl. Neuropsychol. 14, 101–112 (2007).

    PubMed  PubMed Central  Google Scholar 

  66. 66

    Bever, C., Grattan, L., Panitch, H. S. & Johnson, K. P. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult. Scler. 1, 165–169 (1995).

    PubMed  PubMed Central  Google Scholar 

  67. 67

    Benedict, R. H. B. et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult. Scler. 14, 940–946 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Morrow, S. A. et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult. Scler. 16, 1385–1392 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69

    Morrow, S. A., Jurgensen, S., Forrestal, F. & Benedict, R. H. B. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J. Neurol. doi:10.1007/s00415-011-5975-5973.

  70. 70

    Morrow, S. A. et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist 24, 1131–1145 (2010).

    PubMed  PubMed Central  Google Scholar 

  71. 71

    Bodling, A. M., Denney, D. R. & Lynch, S. G. Cognitive aging in patients with multiple sclerosis: a cross-sectional analysis of speeded processing. Arch. Clin. Neuropsychol. 24, 761–767 (2009).

    PubMed  PubMed Central  Google Scholar 

  72. 72

    Amato, M. P., Ponziani, G., Siracusa, G. & Sorbi, S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol. 58, 1602–1606 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73

    Amato, M. P. et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 75, 1134–1140 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  74. 74

    Beatty, W. W. & Aupperle, R. L. Sex differences in cognitive impairment in multiple sclerosis. Clin. Neuropsychol. 16, 472–480 (2002).

    PubMed  PubMed Central  Google Scholar 

  75. 75

    Savettieri, G. et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208–1214 (2004).

    PubMed  PubMed Central  Google Scholar 

  76. 76

    Marrie, R. A., Cutter, G., Tyry, T., Vollmer, T. & Campagnolo, D. Does multiple sclerosis-associated disability differ between races? Neurology 66, 1235–1240 (1235).

    Google Scholar 

  77. 77

    Arnett, P. A., Barwick, F. H. & Beeney, J. E. Depression in multiple sclerosis: review and theoretical proposal. J. Int. Neuropsychol. Soc. 14, 691–724 (2008).

    PubMed  PubMed Central  Google Scholar 

  78. 78

    Morrow, S. A., Weinstock-Guttman, B., Munschauer, F., Hojnacki, D. & Benedict, R. H. B. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult. Scler. 15, 998–1005 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79

    Amato, M. P. et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J. Neurol. 253, 1054–1059 (2006).

    PubMed  PubMed Central  Google Scholar 

  80. 80

    Glanz, B. I. et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult. Scler. 13, 1004–1010 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  81. 81

    Comi, G. et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J. Neurol. Sci. 132, 222–227 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  82. 82

    Filippi, M. et al. Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neurol. 34, 324–328 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. 83

    Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255–265 (2008).

    Google Scholar 

  84. 84

    Hawkes, C. H. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult. Scler. 13, 610–615 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85

    Pittas, F. et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J. Neurol. 256, 577–585 (2009).

    PubMed  PubMed Central  Google Scholar 

  86. 86

    Staff, N. P., Lucchinetti, C. F. & Keegan, B. M. Multiple sclerosis with predominant, severe cognitive impairment. Arch. Neurol. 66, 1139–1143 (2009).

    PubMed  PubMed Central  Google Scholar 

  87. 87

    Ghaffar, O. & Feinstein, A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 71, 164–169 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88

    Messinis, L., Kyprianidou, A., Malefaki, S. & Papathanasopoulos, P. Neuropsychological deficits in long-term frequent cannabis users. Neurology 66, 737–739 (2006).

    PubMed  PubMed Central  Google Scholar 

  89. 89

    Chapman, B. P., Lyness, J. M. & Duberstein, P. Personality and medical illness burden among older adults in primary care. Psychosom. Med. 69, 277–282 (2007).

    PubMed  PubMed Central  Google Scholar 

  90. 90

    Schwartz, E. S., Chapman, B. P., Duberstein, P. R., Weinstock-Guttman, B. & Benedict, R. H. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment 18, 39–49 (2011).

    PubMed  PubMed Central  Google Scholar 

  91. 91

    Benedict, R. H. B. et al. Cortical atrophy and personality in multiple sclerosis. Neuropsychology 22, 432–441 (2008).

    PubMed  PubMed Central  Google Scholar 

  92. 92

    Mahley, R. W. & Rall, S. C. Jr. Apolipoprotein E: far more than a lipid transport protein. Annu.Rev. Genomics Hum. Genet. 1, 507–537 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  93. 93

    Enzinger, C. et al. Accelerated evolution of brain atrophy and “black holes” in MS patients with APOE-ε4. Ann. Neurol. 55, 563–569 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  94. 94

    De Stefano, N. et al. Influence of apolipoprotein E ε4 genotype on brain tissue integrity in relapsing–remitting multiple sclerosis. Arch. Neurol. 61, 536–540 (2004).

    PubMed  PubMed Central  Google Scholar 

  95. 95

    Horáková, D. et al. APOE ε4-positive multiple sclerosis patients develop more gray matter and whole brain atrophy. a 4-year longitudinal study using the 15-year disease onset model. Fol. Biol. Praha 56, 242–251 (2010).

    Google Scholar 

  96. 96

    Ghaffar, O. & Feinstein, A. APOE ε4 and cognitive dysfunction in multiple sclerosis: a review. J. Neuropsychiatry Clin. Neurosci. 22, 155–165 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  97. 97

    Oliveri, R. L. et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol. Scand. 100, 290–295 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98

    Koutsis, G. et al. An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult. Scler. 15, 174–179 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99

    Koutsis, G. et al. APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology 68, 546–549 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100

    Parmenter, B. A., Denney, D. R., Lynch, S. G., Middleton, L. S. & Harlan, L. M. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult. Scler. 13, 25–32 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101

    Savettieri, G. et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208–1214 (2004).

    PubMed  PubMed Central  Google Scholar 

  102. 102

    Ghaffar, O., Reis, M., Pennell, N., O'Connor, P. & Feinstein, A. APOE ε4 and the cognitive genetics of multiple sclerosis. Neurology 74, 1611–1618 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  103. 103

    Portaccio, E. et al. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol. Scand. 120, 439–441 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  104. 104

    van der Walt, A. et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 73, 1018–1025 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  105. 105

    Jensen, C. J. et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS ONE 5, e10003 (2010).

    PubMed  PubMed Central  Google Scholar 

  106. 106

    Zivadinov, R. et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain derived neurotrophic factor (BDNF). Hum. Mol. Genet. 16, 2659–2668 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  107. 107

    Weinstock-Guttman, B. et al. The rs2030324 SNP of brain derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology 18, 43–52 (2010).

    PubMed  PubMed Central  Google Scholar 

  108. 108

    Cerasa, A. et al. The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav. Brain Res. 207, 377–386 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  109. 109

    Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9, 516–526 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  110. 110

    Fazekas, F. et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53, 448–456 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  111. 111

    Bakshi, R., Caruthers, S. D., Janardhan, V. & Wasay, M. Intraventricular CSF pulsation artifact on fast fluid-attenuated inversion-recovery MR images: analysis of 100 consecutive normal studies. AJNR Am. J. Neuroradiol. 21, 503–508 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  112. 112

    Bakshi, R., Ariyaratana, S., Benedict, R. H. & Jacobs, L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch. Neurol. 58, 742–748 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  113. 113

    Truyen, L. et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47, 1469–1476 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  114. 114

    Zivadinov, R. & Bakshi, R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front. Biosci. 9, 665–683 (2004).

    PubMed  PubMed Central  Google Scholar 

  115. 115

    Rao, S. M., Leo, G. J., Haughton, V. M., Aubin-Faubert, P. S. & Bernardin, L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39, 161–166 (1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  116. 116

    Geurts, J. J. et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236, 254–260 (2005).

    PubMed  PubMed Central  Google Scholar 

  117. 117

    Geurts, J. J. et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am. J. Neuroradiol. 26, 572–527 (2005).

    PubMed  PubMed Central  Google Scholar 

  118. 118

    Bagnato, F. et al. T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult. Scler. 16, 1203–1212 (2010).

    PubMed  PubMed Central  Google Scholar 

  119. 119

    Roosendaal, S. D. et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult. Scler. 15, 708–714 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  120. 120

    McDonald, W. I., Miller, D. H. & Barnes, D. The pathological evolution of multiple sclerosis. Neuropathol. Appl. Neurobiol. 18, 319–334 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  121. 121

    Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).

    CAS  Google Scholar 

  122. 122

    Trapp, B. D., Ransohoff, R. & Rudick, R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295–302 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  123. 123

    Peterson, J. W., Bö, L., Mörk, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389–400 (2001).

    CAS  PubMed  Google Scholar 

  124. 124

    van Buchem, M. A. et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 50, 1609–1617 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  125. 125

    Comi, G. et al. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64 (Suppl. 1), S21–S25 (1998).

    PubMed  PubMed Central  Google Scholar 

  126. 126

    Filippi, M. et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68, 157–161 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  127. 127

    Rovaris, M. et al. Cognitive dysfunction in patients with mildly disabling relapsing–remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J. Neurol. Sci. 195, 103–109 (2002).

    PubMed  PubMed Central  Google Scholar 

  128. 128

    Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698–1704 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  129. 129

    Hohol, M. J. et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch. Neurol. 54, 1018–1025 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  130. 130

    Houtchens, M. K. et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 69, 113–123 (2007).

    Google Scholar 

  131. 131

    Benedict, R. H. B. et al. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 14, 44–51 (2002).

    PubMed  PubMed Central  Google Scholar 

  132. 132

    Anderson, V. M. et al. Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Mult. Scler. 16, 1083–1090 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133

    Sicotte, N. L. et al. Regional hippocampal atrophy in multiple sclerosis. Brain 131, 1134–1141 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  134. 134

    Feinstein, A. et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62, 586–590 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  135. 135

    Stern, Y. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271, 1004–1010 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  136. 136

    Stern, Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, S69–S74 (2006).

    PubMed  PubMed Central  Google Scholar 

  137. 137

    Mainero, C. et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 21, 858–867 (2004).

    PubMed  PubMed Central  Google Scholar 

  138. 138

    Chiaravalloti, N. et al. Cerebral activation patterns during working memory performance in multiple sclerosis using fMRI. J. Clin. Exp. Neuropsychol. 27, 33–54 (2005).

    PubMed  PubMed Central  Google Scholar 

  139. 139

    Sumowski, J. F., Chiaravalloti, N., Wylie, G. & Deluca, J. Cognitive reserve moderates the negative effect of brain atrophy on cognitive effi ciency in multiple sclerosis. J. Int. Neuropsychol. Soc. 15, 606–612 (2009).

    PubMed  PubMed Central  Google Scholar 

  140. 140

    Sumowski, J. F., Wylie, G. R., Gonnella, A., Chiaravalloti, N. & Deluca, J. Premorbid cognitive leisure independently contributes to cognitive reserve in multiple sclerosis. Neurology 75, 1428–1431 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  141. 141

    Sumowski, J. F., Wylie, G. R., Deluca, J. & Chiaravalloti, N. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain 133, 362–374 (2010).

    PubMed  PubMed Central  Google Scholar 

  142. 142

    O'Brien, A. R., Chiaravalloti, N., Goverover, Y. & Deluca, J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch. Phys. Med. Rehabil. 89, 761–769 (2008).

    PubMed  PubMed Central  Google Scholar 

  143. 143

    Chiaravalloti, N. D., DeLuca, J., Moore, N. B. & Ricker, J. H. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult. Scler. 11, 58–68 (2005).

    PubMed  PubMed Central  Google Scholar 

  144. 144

    Waxman, S. G. Membranes, myelin, and the pathophysiology of multiple sclerosis. N. Engl. J. Med. 306, 1529–1533 (1982).

    CAS  PubMed  PubMed Central  Google Scholar 

  145. 145

    Bever, C. T. Jr et al. Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47, 1457–1462 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  146. 146

    Bever, C. T. Jr et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054–1059 (1994).

    PubMed  PubMed Central  Google Scholar 

  147. 147

    Rossini, P. M. et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7, 354–358 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  148. 148

    Geisler, M. W. et al. The effects of amantadine and pemoline on cognitive funcitoning in multiple sclerosis. Arch. Neurol. 53, 185–188 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  149. 149

    Wilken, J. A. et al. Treatment of multiple sclerosis related cognitive problems with adjunctive modafinil: Rationale and preliminary supportive data. Int. J. MS Care 10, 1–10 (2008).

    Google Scholar 

  150. 150

    Harel, Y., Appleboim, N., Lavie, M. & Achiron, A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J. Neurol. Sci. 276, 38–40 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  151. 151

    Benedict, R. H. et al. Effects of L-amphetamine sulfate on cognitive function in multiple sclerosis patients. J. Neurol. 255, 848–852 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  152. 152

    Morrow, S. A. et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J. Neurol. 256, 1095–1102 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  153. 153

    Krupp, L. B. et al. Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurology 63, 1579–1585 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  154. 154

    Krupp, L. et al. A multi-center randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (in press).

  155. 155

    Shaygannejad, V., Janghorbani, M., Ashtari, F., Zanjani, H. A. & Zakizade, N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can. J. Neurol. Sci. 35, 476–481 (2008).

    PubMed  PubMed Central  Google Scholar 

  156. 156

    Sumoski, J. F. et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult. Scler. (in press).

  157. 157

    Benedict, R. & Bobholz, J. Multiple sclerosis. Semin. Neurol. 27, 78–86 (2007).

    PubMed  PubMed Central  Google Scholar 

  158. 158

    Chapman, B. P., Duberstein, P. & Lyness, J. M. The distressed personality type: replicability and general health associations. Eur. J. Personality (2007).

  159. 159

    Smits, R. C. et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44, 1701–1705 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

R. H. B. Benedict and R. Zivadinov contributed equally to researching, discussing, writing, reviewing and editing this article.

Corresponding author

Correspondence to Ralph H. B. Benedict.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Benedict, R., Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7, 332–342 (2011). https://doi.org/10.1038/nrneurol.2011.61

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing